知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

12 条记录 (耗时 0.043 秒)

    TRACK DRIVE SYSTEM
    4.
    发明申请
    TRACK DRIVE SYSTEM 有权
    跟踪驱动系统

    公开(公告)号：US20060213700A1

    公开(公告)日：2006-09-28

    申请号：US11277405

    申请日：2006-03-24

    申请人： William Hildebrand

    发明人： William Hildebrand

    IPC分类号： B62D55/00

    CPC分类号： B62D55/00 ,  B60G2300/32 ,  B62D55/104 ,  B62D55/12

    摘要： A track drive system comprises a chassis frame and a drive wheel rotatably coupled to the chassis frame. An upper idler is rotatably coupled to the chassis frame rearwardly of the drive wheel. A forward idler is rotatably coupled to the chassis frame below the drive wheel. A suspended frame is pivotally coupled to the chassis frame by upper and lower swing arms. A rear idler is rotatably coupled to a rear portion of the suspended frame at a location displaced generally downwardly from an attachment point of the upper swing arm by a rear idler offset distance. A lower idler is rotatably coupled to a forward portion of the suspended frame. A biasing means biases the suspended frame away from the chassis frame.

    摘要翻译： 轨道驱动系统包括底盘框架和可旋转地联接到底盘框架的驱动轮。 上部惰轮可旋转地联接到驱动轮后方的底盘框架。 前进惰轮可旋转地联接到驱动轮下方的底盘框架。 悬挂的框架通过上下摆臂枢转地联接到底盘框架。 一个后惰轮在悬臂的后部可旋转地联接到悬臂的后部，该位置大体上从上摆臂的附接点向下偏移一个后空转距离。 下部惰轮可旋转地联接到悬挂框架的前部。 偏置装置将悬挂的框架偏离底盘框架。

    Comparative ligand mapping from MHC class I positive cells
    5.
    发明申请
    Comparative ligand mapping from MHC class I positive cells 审中-公开
    来自MHC I类阳性细胞的比较配体图谱

    公开(公告)号：US20070099182A1

    公开(公告)日：2007-05-03

    申请号：US11591118

    申请日：2006-11-01

    申请人： William Hildebrand ,  Angela Wahl ,  Curtis McMurtrey

    发明人： William Hildebrand ,  Angela Wahl ,  Curtis McMurtrey

    IPC分类号： C12Q1/70 ,  C12Q1/68 ,  C07K7/08 ,  C07K7/06

    CPC分类号： C07K7/08 ,  C07K7/06

    摘要： The present invention relates generally to a methodology for the isolation, purification and identification of peptide ligands presented by MHC positive cells. In particular, the methodology of the present invention relates to the isolation, purification and identification of these peptide ligands from soluble class I and class 11 MHC molecules which may be from uninfected, infected, or tumorigenic cells. The methodology of the present invention broadly allows for these peptide ligands and their cognate source proteins thereof to be identified and used as markers for infected versus uninfected cells and/or tumorigenic versus nontumorigenic cells, with said identification being useful for marking or targeting a cell for therapeutic treatment or priming the immune response against infected cells.

    摘要翻译： 本发明一般涉及由MHC阳性细胞提供的肽配体的分离，纯化和鉴定的方法。 特别地，本发明的方法涉及从可能来自未感染，感染或致瘤细胞的可溶性I类和11类MHC分子中分离，纯化和鉴定这些肽配体。 本发明的方法广泛地允许鉴定这些肽配体及其同源来源蛋白，并将其用作感染与未感染细胞和/或致瘤性与非致癌性细胞的标记，所述鉴定可用于标记或靶向细胞 治疗性治疗或引发针对感染细胞的免疫应答。

    Accelerated class I and class II HLA DNA sequence-based typing
    6.
    发明申请
    Accelerated class I and class II HLA DNA sequence-based typing 审中-公开
    加速I类和II类HLA DNA序列分型

    公开(公告)号：US20070065860A1

    公开(公告)日：2007-03-22

    申请号：US11523981

    申请日：2006-09-20

    申请人： William Hildebrand ,  Steven Cate ,  Runying Tian

    发明人： William Hildebrand ,  Steven Cate ,  Runying Tian

    IPC分类号： C12Q1/68 ,  C12P19/34

    CPC分类号： C12Q1/6876 ,  C12Q1/6881 ,  C12Q2600/156

    摘要： There is provided a method for directly typing or sequencing HLA class I or class II alleles from a tissue sample wherein at least one exon of the HLA class I or class II alleles from the sample is amplified in a locus specific manner utilizing two primers, wherein at least one of the primers has a universal or generic sequencing primer site incorporated therein. After amplification, the amplified exon(s) are directly sequenced, and a comparison is made between the derived HLA allele sequence and an HLA allele database, thereby giving an exact HLA type for the sample being tested.

    摘要翻译： 提供了一种用于从组织样品直接分型或测序HLA I类或II类等位基因的方法，其中使用两个引物以特异性位点的方式扩增来自样品的HLA I类或II类等位基因的至少一个外显子，其中 至少一个引物具有并入其中的通用或通用测序引物位点。 扩增后，扩增的外显子被直接测序，并且在得到的HLA等位基因序列和HLA等位基因数据库之间进行比较，从而给出被测试样品的精确HLA类型。

    Class I sequence based typing of HLA-A, -B, and -C alleles by direct DNA sequencing
    8.
    发明申请
    Class I sequence based typing of HLA-A, -B, and -C alleles by direct DNA sequencing 审中-公开
    通过直接DNA测序对HLA-A，-B和-C等位基因进行I类序列分型

    公开(公告)号：US20070128629A1

    公开(公告)日：2007-06-07

    申请号：US11524092

    申请日：2006-09-20

    申请人： William Hildebrand ,  Mary Ellexson ,  Pierre Chretlen ,  R. Duthie

    发明人： William Hildebrand ,  Mary Ellexson ,  Pierre Chretlen ,  R. Duthie

    IPC分类号： C12Q1/68 ,  C12P19/34

    CPC分类号： C12Q1/6881 ,  C12Q2600/156

    摘要： There is provided a method for directly typing or sequencing HLA-A, -B, or -C alleles from a tissue sample wherein exons 2 and 3 of the HLA-A, -B, or -C alleles from the sample are amplified together in a locus specific manner and then separated out and individually amplified in a locus specific manner. After the two amplifications, the amplified exons are directly sequenced, the sequences are recombined, and a comparison is made between the derived HLA allele sequence and an HLA allele database, thereby giving an exact HLA-A, -B, or -C type for the sample being tested.

    摘要翻译： 提供了一种用于从组织样品直接分型或测序HLA-A，-B或-C等位基因的方法，其中来自样品的HLA-A，-B或-C等位基因的外显子2和3在一起扩增 特异性位点，然后以特异性方式分离出并单独扩增。 在两个扩增后，扩增的外显子被直接测序，序列重组，并且在得到的HLA等位基因序列和HLA等位基因数据库之间进行比较，由此给出精确的HLA-A，-B或-C型 样品正在测试。

    Epitope testing using soluble HLA
    9.
    发明申请
    Epitope testing using soluble HLA 审中-公开
    使用可溶性HLA的表位测试

    公开(公告)号：US20070026433A1

    公开(公告)日：2007-02-01

    申请号：US11451567

    申请日：2006-06-12

    申请人： William Hildebrand ,  Rico Buchli

    发明人： William Hildebrand ,  Rico Buchli

    IPC分类号： C12Q1/68 ,  G01N33/53

    CPC分类号： G01N33/6878 ,  G01N33/56977 ,  G01N2333/70539

    摘要： The present invention relates generally to a methodology for assaying the binding of a peptide to an individual, specific, soluble HLA molecule using fluorescence polarization. The peptides utilized in the method may be identified by indirect methods utilizing T lymphocytes, or by a direct method of epitope discovery described herein.

    摘要翻译： 本发明一般涉及使用荧光偏振来测定肽与个体特异性可溶性HLA分子的结合的方法。 在该方法中使用的肽可以通过使用T淋巴细胞的间接方法或通过本文所述的表位发现的直接方法来鉴定。